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Abstract
Background
Early revascularization of ischemic organs is key to improving outcomes, yet consequent
reperfusion injury may be harmful. Reperfusion injury is largely attributed to excess mito-
chondrial production of reactive oxygen species (ROS). Sulfide inhibits mitochondria and
reduces ROS production. Ammonium tetrathiomolybdate (ATTM), a copper chelator,
releases sulfide in a controlled and novel manner, and may offer potential therapeutic
utility.
Methods and findings
In vitro, ATTM releases sulfide in a time-, pH-, temperature-, and thiol-dependent manner.
Controlled sulfide release from ATTM reduces metabolism (measured as oxygen con-
sumption) both in vivo in awake rats and ex vivo in skeletal muscle tissue, with a superior
safety profile compared to standard sulfide generators. Given intravenously at reperfu-
sion/resuscitation to rats, ATTM significantly reduced infarct size following either myocar-
dial or cerebral ischemia, and conferred survival benefit following severe hemorrhage.
Mechanistic studies (in vitro anoxia/reoxygenation) demonstrated a mitochondrial site
of action (decreased MitoSOX fluorescence), where the majority of damaging ROS is
produced.
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Conclusions
The inorganic thiometallate ATTM represents a new class of sulfide-releasing drugs. Our
findings provide impetus for further investigation of this compound as a novel adjunct ther-
apy for reperfusion injury.
Author summary
Why was this study done?
• Reperfusion injury results from restoration of blood flow to ischemic organs, e.g., fol-
lowing myocardial or cerebral revascularization or resuscitation from hemorrhage.
Reperfusion injury may be as severe as the initial ischemic event, yet there is no cur-
rently approved treatment.
• Sulfide-releasing drugs are known to be effective against reperfusion injury in animal mod-
els, but none to date have shown efficacy in patients, and safety concerns have been raised.
What did the researchers do and find?
• We found that ammonium tetrathiomolybdate (ATTM) releases sulfide in a controlled
manner and potentially fits the desired efficacy and safety profile. The chemical nature
of sulfide release from ATTM differs from that of other sulfide-releasing drug classes.
• In our animal models, ATTM decreased oxygen metabolism and protected against
reperfusion injury and organ damage following heart attack, stroke, and hemorrhage,
with significant improvements in outcome, and a good safety profile.
What do these findings mean?
• We have discovered a novel class of sulfide-releasing drugs. In our animal models,
ATTM protected body organs from damage induced by reperfusion of ischemic tissues.
• ATTM could be potentially used in patients as a short-term protective therapy while
blocked blood vessels feeding major organs such as the brain and heart are being opened
up, or during resuscitation from severe bleeding. Effectiveness and safety (short- and
long-term) need to be explored in humans.
• If ATTM can be successfully developed, it could significantly reduce long-term organ
damage after heart attack, stroke, hemorrhage, and other ischemia/reperfusion conditions.
Introduction
Ischemia/reperfusion (I/R) injury is well recognized following multiple therapeutic interven-
tions such as revascularization following myocardial ischemia or cerebrovascular thrombosis,
resuscitation following hemorrhage, and organ transplantation. Following injurious reduction
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of blood flow to tissues, further damage is induced by reperfusion, necessarily caused by resto-
ration of an adequate oxygen supply. Reperfusion injury is largely attributed to excess produc-
tion of reactive oxygen species (ROS) by mitochondria [1].
The development of highly effective reperfusion therapies such as percutaneous coronary
intervention and thrombolysis has revolutionized acute management. However, residual mor-
bidity from both irreversible ischemia (from delayed intervention) and reperfusion injury
(from the intervention itself) still represents a considerable social and economic healthcare
burden, leading to chronic organ failure and a shortened lifespan. Indeed, of noncommunic-
able diseases, the most recent Global Burden of Disease Study cites cardiovascular disease as
the leading cause of mortality worldwide [2]. Multiple strategies to prevent or minimize reper-
fusion injury have to date proved unsuccessful in clinical trials [3,4].
A landmark paper in 2005 showed that inhalation of H2S by mice induced a profound,
reversible hypometabolic state of “suspended animation” [5]. This effect is mediated by inhibi-
tion of cytochrome C oxidase, the terminal complex of the mitochondrial respiratory chain
[6]. H2S is moderately water-soluble, partitioning between aqueous and gas/lipid compart-
ments; as a weak acid, it deprotonates following dissolution to form a hydrosulfide anion
(HS−), with negligible concentrations of S2− at physiological pH [7]. Unless stated otherwise,
all three forms herein are referred to as “sulfide.” Applied either in the form of gaseous H2S or
as an intravenous (IV) sodium salt (Na2S), sulfide was shown to protect against lethal hemor-
rhage [8] and hypoxia [9] in small rodent models. However, attempts to induce hypometabo-
lism and improve outcomes in larger mammals following severe cardiorespiratory insults
yielded variable results [10,11]. A clinical trial of Na2S in coronary artery bypass surgery was
stopped prematurely in 2010 [12] for reasons still not published. A burgeoning literature on
novel sulfide-releasing drugs reports encouraging results in experimental studies of I/R injury
[13], though none of these newer products have yet been tested clinically.
Thiomolybdates were first synthesized nearly two centuries ago [14]. The ammonium salt,
ammonium tetrathiomolybdate (ATTM) ([NH4]2MoS4), has been used off-label for decades as
an oral copper chelator to treat Wilson disease in humans [15] and shows utility against copper
toxicity in sheep [16]. In three patients with Wilson disease, IV dosing of ATTM was reported
to have a copper-lowering effect with no reported safety concerns [17]. In animal models,
ATTM has proven beneficial across myriad experimental pathologies including fibrotic, auto-
immune, and malignant diseases; copper-handling ability, with subsequent anti-inflammatory
and anti-angiogenic effects, is presumed responsible for its efficacy [18]. Upon dissolving
ATTM into aqueous solution, we noted the pungent rotten egg odor characteristic of sulfide
[19], a finding not formally documented in the medical literature. Our characterization of
ATTM revealed that it belongs to a new class of inorganic sulfide-releasing molecules, the thio-
metallates, in which one or more sulfur atoms are covalently bound to a transition metal. We
hypothesized that ATTM could (1) reduce metabolism through graded inhibition of oxidative
phosphorylation, (2) confer protection in both whole animal and organ-specific models of I/R
injury, and (3) offer a superior safety profile to a benchmark sulfide generator.
Methods
Ethics, animals, and husbandry
Male Wistar rats (approximately 300 g body weight) were used in all in vivo studies. Use of
this species allows greater blood sampling than is possible with mice. Importantly, mice
markedly and rapidly reduce their metabolism in response to a severe systemic insult, whereas
rats more closely mimic human responses [20]. Use of mice would likely confound evaluation
of a metabolism-modifying agent. All experiments (except brain I/R studies) were performed
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in the UK according to local ethics committee (University College London) and UK Home
Office guidelines under the Animals (Scientific Procedures) Act 1986. Brain I/R studies (per-
formed in Brazil) were carried out in accordance with Brazilian National Council for the Con-
trol of Animal Experimentation (CONCEA) guidelines. Animals used for UK- and Brazil-
based studies were purchased from Charles River Laboratories (Margate, UK) or bred in-
house at the University of Southern Santa Catarina (Criciu´ma, Brazil), respectively. All animals
were healthy and certified pathogen-free, and housed in cages of four individuals on a 12-h
light/dark cycle, with food and water ad libitum prior to experimentation. Standard cages and
bedding were used. Additional tissue paper was provided for comfort, and cardboard tubes for
cage enrichment. All experiments were started at 9 A.M. local time. All animals were anesthe-
tized with isoflurane (Abbott, Maidenhead, UK). Where mechanical ventilation was used, the
anesthetic was switched to intraperitoneal sodium pentobarbitone (Pentoject; Animalcare,
York, UK) just prior to intubation. Perioperative analgesia was provided by buprenorphine,
0.05 mg/kg subcutaneously (Reckitt Benckiser, Slough, UK), or dipyrone, 80 mg/kg subcutane-
ously (Laborato´rio Teuto Brasileiro, Ana´polis, Brazil). Euthanasia at experiment end was per-
formed by IV sodium pentobarbitone.
In vitro sulfide release
Free sulfide (H2S gas) liberated from ATTM or NaHS (sodium hydrosulfide; Alfa Aesar, Hey-
sham, UK) was measured following dissolution of the compounds in phosphate-buffered
saline at room temperature; the H2S gas was captured in the headspace of airtight (further
sealed with Parafilm; Bemis, Neenah, WI) 50-ml Falcon tubes (Corning Science Mexico, Rey-
nosa, Mexico). Aliquots of the ATTM stock were rapidly diluted 1:10 with phosphate-buffered
saline that was pH- or temperature-adjusted or contained thiols (L-cysteine or reduced gluta-
thione [GSH], both 5 mM final concentration), as required (n = 3–6/group). The liquid and
gas (headspace) phases comprised 5 and 45 ml, respectively. Following incubation, 5 ml of
headspace gas was sampled and passed through a commercially available H2S detector
(Z900XP; Environmental Sensors, Boca Raton, FL); peak H2S gas concentrations were
recorded. We used ATTM purchased from a single supplier (Sigma-Aldrich, Gillingham, UK)
on all but one occasion. Since the compound purchased elsewhere (Strem Chemicals, New-
buryport, MA) was chemically dissimilar (ultraviolet—visible spectroscopy and sulfide
release), we used the Sigma-Aldrich compound for all experiments. Unless stated otherwise, all
other chemicals/reagents were purchased from Sigma-Aldrich.
In separate experiments, total sulfide concentrations from ATTM (n = 6) and NaHS (n = 5)
at different pH levels (diluted as above, with a liquid:gas phase ratio of 0.67:0.33) were obtained
via incubation, derivatization, then measurement using a high-performance liquid chromatog-
raphy (HPLC)–based monobromobimane (MBB) assay, as previously described [21,22], modi-
fied and elaborated upon as described in S1 Text. We used 0.55 mM ATTM and 2.2 mM
NaHS to yield comparable quantities of total sulfur.
In vivo sulfide detection
Anesthetized animals underwent carotid arterial and jugular venous cannulation for blood
sampling and drug administration, and a tracheostomy to secure the airway; a more detailed
description is provided in S1 Text. After 30 min stabilization, either ATTM (0.25 mg/kg,
n = 4) or NaHS (1 mg/kg, n = 3) was dissolved in 0.9% saline and (within 2 min) administered
as an IV bolus (1 ml/kg) over 5 s. Plasma was obtained to measure sulfide concentrations at
frequent intervals from 15 s to 120 min post-administration. In separate studies, ATTM (10 or
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20 mg/kg/h, n = 4/group) was continually infused intravenously, with samples taken from 5 to
180 min after infusion onset.
Ex vivo metabolic study
Soleus muscle tissue was obtained from anesthetized animals and dissected, and the resulting
fibers permeabilized with saponin. After 20 min incubation, saponin and its metabolites were
removed by washing the fibers three times in ice-cold respiratory medium (see S1 Text for fur-
ther detail). Oxygen consumption (VO2) was assessed in small bundles of tissue using a Clark-
type oxygen electrode (Rank Brothers, Bottisham, UK); this was connected to a sealed chamber
and maintained at 37˚C. VO2 was determined as the fall in oxygen concentration within the
chamber over time. Substrates for mitochondrial respiratory chain complexes I and II were
added to the medium, which was subsequently oxygenated to 250 μM O2 using 100% oxygen
gas. Two series of experiments were performed. In the first, VO2 was assessed following vehicle
(n = 8) or increasing concentrations of ATTM (2–32 mM total sulfur, n = 8), NaHS (0.5–4
mM, n = 3), or combined non-sulfide-containing copper chelators (neocuproine and cupri-
zone, both 1–100 μM). In the second, tissues respired to hypoxia following addition of either
vehicle (n = 12), ATTM (2 mM total sulfur, n = 9), NaHS (0.5 mM, n = 4), or copper chelators
(100 μM, n = 7), added at 200 μM O2. Oxygen consumption was determined from 175 to
75 μM O2 at 25 μM intervals and compared to baseline values recorded prior to the addition of
drugs.
In vivo metabolic study
Anesthetized animals had arterial and venous lines tunneled subcutaneously to the nape of the
neck. The lines were then attached to a swivel tether system (Linton Instrumentation, Diss,
UK), and the animals then placed into metabolic chambers (Oxymax system; Columbus
Instruments, Columbus, OH), where they were allowed to recover. These chambers enable
continuous measurement of whole body O2 consumption. Animals were acclimatized for 24 h
and frequently assessed using an in-house clinical scoring system before inclusion into two
separate studies (n = 4/group). Short-term changes in O2 consumption were assessed following
increasing, hourly IV bolus doses of ATTM (2–20 mg/kg). Controls received equivalent vol-
umes of saline (2 ml/kg per bolus). Longer-term effects on oxygen consumption were assessed
following continuous IV infusions of ATTM (10 mg/kg/h for 24 h) or an equivalent volume of
saline (10 ml/kg/h). At the end of each long-term metabolic experiment, animals were re-anes-
thetized, core temperature was measured rectally, and heart rate determined using echocardi-
ography (see S1 Text).
Pharmacokinetic/pharmacodynamic and safety studies
Mechanically ventilated animals were anesthetized with isoflurane during instrumentation
and with sodium pentobarbitone thereafter. After a stabilization period, they received increas-
ing IV bolus doses of ATTM (1–100 mg/kg, n = 3), the bis-choline salt of ATTM (ATN-224,
1–100 mg/kg, n = 3), or NaHS (0.01–1 mg/kg, n = 4). Ventilator (PhysioSuite; Kent Scientific,
Torrington, CT) settings were as follows: tidal volume, 10 ml/kg; respiratory rate, 80/min; and
positive end-expiratory pressure, 3 cm H2O. H2S in exhaled breath was measured by connect-
ing the ventilator exhaust to the (above) H2S detector. Measurements were collected at base-
line, then as follows after each dose: blood pressure and exhaled H2S (peak change or level)
within 30 s, myocardial function (by echocardiography [see S1 Text]) within 1 min, blood
sampling to determine plasma concentration at 2 min, and arterial blood gas analysis (to mea-
sure partial pressure of O2 [PaO2] and CO2 [PCO2], glucose, lactate, and acid/base changes) at
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27 min; doses were escalated every 30 min. For ATTM and ATN-224, the absorbance (at 468
nm) of plasma samples was assessed using a microplate reader and BioTek (Gen5) software
(Synergy 2, North Star Scientific, Sandy, UK). Plasma concentrations were derived by compar-
ison against standard curves. In separate studies assessing safety, spontaneously breathing,
instrumented rats received either ATTM (10 mg/kg IV bolus, then 20 mg/kg/h, n = 11) or 0.1
M hydrochloric acid (10 ml/kg/h, n = 5) for 5 h. A subset of ATTM-treated animals received
70% inspired oxygen from 3 h onwards (n = 7). Vehicle-treated animals (n = 10) received
equivalent volumes of 0.9% saline. Blood pressure, echocardiography, arterial blood gas analy-
sis, and vastus lateralis tissue oxygen tension (measured using an indwelling fiber-optic sensor;
Oxford Optronix, Abingdon, UK) were determined at baseline, then hourly. Whole blood
was removed (at baseline, 3 h, and 5 h) and stored (−80˚C) for subsequent measurement of
sulfhemoglobin.
Sulfhemoglobin
In vivo samples were defrosted and immediately diluted (1:10) in human erythrocyte lysing
solution [23]. After 5 min, samples were centrifuged, and sulfhemoglobin measured by absor-
bance of the supernatant at 620 nm, using a microplate reader, as above. To express the sulfhe-
moglobin level as a percentage, oxyhemoglobin level was measured at 577 nm in baseline
samples to obtain total hemoglobin, and adjusted for protein content based on blood gas
machine-derived values at later time points. In separate experiments, concentration response
curves were constructed using naïve rat blood, spiked and incubated (at 37˚C for 60 min) with
either ATTM or NaHS (0.3–100 mM total sulfur, n = 3/group). Sulfhemoglobin was subse-
quently measured as above.
Myocardial and cerebral ischemia/reperfusion
For the myocardial model, anesthetized (with isoflurane during instrumentation and sodium
pentobarbitone thereafter), mechanically ventilated rats (settings as above) received IV fluids
(2.5% glucose in 0.9% saline infused throughout; 10 mg/kg/h). Blunt thoracotomy of the left
fourth intercostal space was performed to access the thoracic cavity. The pericardium was
removed, and the left anterior descending (LAD) coronary artery ligated with 6–0 Mersilk
suture (Ethicon, Edinburgh, UK) 8 mm from the apex for 30 min. Reperfusion was initiated
by untying the LAD suture. The chest wall was then closed. At experiment end (4 h post-reper-
fusion), blood was removed for biomarker analysis, the chest reopened, the pulmonary artery
ruptured, and the heart retrogradely perfused via the carotid artery with 10 ml of 0.9% saline.
The LAD suture was then closed, and the heart perfused in vivo with Evans blue dye (1 ml of a
0.5% solution). Hearts were excised and stored for later batch analysis of area at risk and
infarct size.
For brain I/R studies, animals were anesthetized and instrumented, and ischemia initiated
by bilateral carotid artery occlusion for 25 min. Animals then recovered, receiving analgesia
immediately and 12 h after surgery (dipyrone, 80 mg/kg subcutaneously). At experiment end
(24 h post-reperfusion), animals were re-anesthetized, blood was removed for biomarker anal-
ysis (by cardiac puncture), and brains were removed for assessment of infarct size.
For both organ-specific models, animals were randomized to receive vehicle (0.9% saline,
n = 6/group) or ATTM treatment (10 mg/kg IV bolus, n = 6/group) immediately prior to
reperfusion, thus mimicking a clinical scenario. ATTM-treated animals received a further IV
infusion (10 mg/kg/h) for 60 min, equaling a total dose of 20 mg/kg. Control animals received
equivalent volumes of 0.9% saline.
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Four heart (distal to the LAD suture) and brain slices were incubated with 0.1% tetrazolium
chloride for 20 min, then fixed with 10% formalin for 30 min. Open access software (Image J,
1.49e; National Institutes of Health, Bethesda, MD) was used to quantify the area at risk (not
perfused with Evans blue) and viable tissue (stained with tetrazolium chloride). For the heart
model, we prospectively constrained the area at risk as a proportion of the left ventricular area
studied to fall within 1.5 standard deviations of the median. This equated to values between
25% and 75%, with outliers (10% of cases) being excluded from further analysis. B-type natri-
uretic peptide (BNP; for heart) and S100 calcium binding protein β (S100β; for brain) were
assayed using commercially available kits (Life Diagnostics, Stoke-on-Trent, UK); assays were
performed in duplicate and according to the manufacturer’s instructions.
Global ischemia/reperfusion
Anesthetized, spontaneously breathing animals were subjected to global ischemia by removal
of 50% of estimated blood volume (35 ml/kg) over 15 min, then were monitored for a further
90 min before randomization to receive ATTM (10 mg/kg IV, n = 16) or an equivalent volume
of saline (n = 16). If the mean arterial blood pressure fell below 40 mm Hg during the ischemia
phase, animals were administered 1 ml/kg of 0.9% saline IV. Reperfusion was commenced by
re-infusing autologous shed blood over 15 min. In ATTM-treated animals, the blood was sup-
plemented with a further 2.5 mg/kg, equaling a total dose of 12.5 mg/kg. The primary endpoint
for this study was 6 h mortality, with the animals kept under anesthesia throughout. Animals
were monitored with measurements (as above) performed at baseline, before reperfusion, and
hourly after reperfusion. Blood (replaced by twice volume 0.9% saline) was removed 2 h post-
reperfusion for measurement of interleukin-6 (IL-6) and plasma markers of oxidative stress
and redox status (protein carbonyls, oxidized glutathione [GSSG], and GSH). IL-6 (Millipore,
Billerica, MA) and protein carbonyls (OxiSelect Protein Carbonyl Spectrophotometric Assay;
Cell Biolabs, San Diego, CA) were measured using standard bioassay kits and assayed in dupli-
cate; assays were performed according to the manufacturer’s instructions. GSH and total gluta-
thione were measured in whole blood using HPLC (Jasco, Easton, MD) with fluorescence
detection—excitation and emission at 385 and 515 nm, respectively—with HPLC columns
(C18) and glutathione detection kits from Chromsystems Instruments & Chemicals (Gra¨felf-
ing, Germany).
In vitro anoxia/reoxygenation
Cultured H9C2 (cardiomyoblast) cells were plated (onto six-well Corning Costar cell culture
plates) at a density of 60 × 103/well. Culture medium was replaced with serum-free Dulbecco’s
Modified Eagle Medium (Thermo Fisher Scientific, Loughborough, UK) 24 h later, and adher-
ent cells placed into an anoxic chamber (95% N2 and 5% CO2) for a further 24 h. Reoxygena-
tion was initiated by substitution with fresh (“normoxic”) culture medium supplemented with
ATTM (0.055–5.5 mM, n = 3/group). Viability was assessed 2 h post-reoxygenation using an
Annexin V—propidium iodide—based assay. Briefly, cells were washed, resuspended in 100 μl
of allophycocyanin—Annexin V (BD Biosciences, Oxford, UK) binding buffer (150 mM NaCl,
10 mM HEPES [pH 7.4], 10 mM CaCl2), and stained for 15 min at room temperature in dark
conditions. To assess ROS production, cells were loaded with MitoSOX Red mitochondrial
superoxide indicator (5 μM; Thermo Fisher Scientific, Loughborough, UK) for 30 min [24].
Data were acquired and analyzed by flow cytometry (FACSCalibur; BD CellQuest, BD Biosci-
ences, Oxford, UK) and FlowJo (v. IX; FlowJo, Ashland, OR), respectively.
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Study design, data, and statistics
In vivo I/R and metabolic studies were performed using 1×1 and 2×2 study designs, respec-
tively. For in vivo studies with>2 treatment groups, animals were randomly allocated on the
day of experimentation. Experiments could not be performed in a blinded fashion due to the
distinctive coloration and sulfurous odor of ATTM. However, all biochemistry (biomarker
measurement) and histology (infarct size determination) studies were undertaken by investi-
gators unaware of the treatment allocation. Data are presented as mean ± standard error or
median, quartiles, and range. Pharmacokinetic data were analyzed using a two-phase decay
curve and least squares fitting method. Survival times were analyzed using a log-rank test.
Parametric data were analyzed using repeated measures one- or two-way ANOVA followed by
Bonferroni’s post hoc testing, as appropriate. Nonparametric data were analyzed using the
Mann—Whitney U test. All statistical analyses were two-tailed and were performed using
Prism 7.0.1 software (GraphPad Software, San Diego, CA). This software considers the num-
ber of comparisons and automatically adjusts the probability value following multiple compar-
isons. The number of comparisons varied with the study design. Where a number of treatment
groups (n) are solely compared to the control arm, the α-level is defined, as per usual conven-
tion, as α/n. Where comparison is sought within groups, n reflects the total number of com-
parisons. The p-values reported herein following multiple comparisons are “multiplicity-
adjusted” rather than “exact” p-values. After adjustment (as required), p-values< 0.05 were
considered statistically significant.
Results
Sulfide release studies
We first assessed sulfide release from ATTM or NaHS in vitro by measuring H2S concentra-
tions in the headspace of airtight vials containing buffered aqueous solutions. When dissolved
and incubated at physiological pH and temperature for 1 h, the amount of H2S generated was,
as expected, dependent on the concentration for both compounds. However, at this time
point, approximately 300 times the amount of ATTM (adjusted for total sulfur content) was
required to achieve H2S levels comparable to those observed with NaHS (Fig 1A). At a fixed
concentration, H2S release from ATTM was dependent on time, pH, and temperature, with
more acidic and warmer conditions favoring sulfide release (Fig 1B–1D). ATTM released sul-
fide slowly, in a linear manner over time, whereas H2S levels from NaHS were rapidly gener-
ated and, consequently, similar at all time points (Fig 1B). Co-incubation with thiols (either L-
cysteine or GSH) resulted in a 6-fold increase in H2S release from ATTM (Fig 1E).
To confirm that sulfide release from ATTM was not related to impurities of a particular
batch, we tested five different vials from the same commercial supplier (Sigma-Aldrich)
obtained over a 3-y period. With the exception of an additional batch where the compound
was purchased elsewhere (see Methods), gaseous H2S production was similar when incubated
for 1 h under physiological conditions (3–4 ppm, n = 3/group; S1 Fig).
Sulfide release from ATTM was further confirmed both in vitro and in vivo using the gold-
standard MBB assay [21]. We modified this assay to include L-cysteine to facilitate sulfide
detection by removing excess MBB before chromatographic separation. This induces thiol-
dependent release of sulfide from ATTM; between pH 4.5 and 10 in vitro, ATTM releases
approximately 80% of its bound sulfur as sulfide under these conditions (S2A Fig). While sul-
fide released from ATTM is detectable using an alternative methodology, our modified assay
reflects total, rather than free, sulfide. NaHS, the sulfide generator, was not affected by changes
in pH, with 90% of total sulfide recovered in vitro (between pH 2 and 10) using the MBB assay.
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ATTM elevated MBB-derived plasma sulfide levels when given as either an IV bolus (0.25
mg/kg; S3A Fig) or by continuous infusion (10 and 20 mg/kg/h; S3B Fig). The pharmacoki-
netic profile of ATTM following IV bolus administration showed that disappearance from the
bloodstream was biphasic, yielding distribution (fast) and elimination (slow) half-lives of 1
and 20 min, respectively (S3D Fig). By contrast, the distribution half-life of NaHS was three
times faster than that of ATTM; since plasma sulfide levels normalized within 1 min post-
administration (S3C and S3D Fig), the elimination half-life was not determined. Notably, no
adverse events were recorded using these doses of ATTM. Bolus IV doses of NaHS in excess of
1 mg/kg resulted in mortality.
Modulation of metabolism
We assessed the impact of ATTM on metabolism using a range of ex vivo and in vivo assays.
Both NaHS and ATTM inhibited oxygen consumption ex vivo in permeabilized rat soleus
muscle, with an IC50 (concentration causing 50% inhibition) of 1.6 and 11.6 mM, respectively
(Fig 2A). As oxygen consumption is dependent on [O2]< 150 μM in this model, these experi-
ments were performed in relative “normoxia,” between 150 and 250 μM O2. In separate experi-
ments, we applied a single concentration and allowed tissues to respire to hypoxia. ATTM (2
mM total sulfur) and NaHS (0.5 mM) significantly (p< 0.05) inhibited oxygen consumption
(versus vehicle; Fig 2B). Notably, the concentration of ATTM that could inhibit oxygen
Fig 1. In vitro release of gaseous H2S from ATTM and NaHS under different environmental conditions.
Comparison of ammonium tetrathiomolybdate (ATTM) and NaHS with changes in (A) concentration and (B) time. In (A),
the molarity of each compound was adjusted for equal total sulfur content; drugs were incubated for 1 h at physiological
pH (7.4) and temperature (37˚C). In (B), fixed concentrations were used: ATTM 100 mM (total sulfur) and NaHS 0.3 mM.
The effects of pH, temperature, and the presence of thiols on H2S gas released from ATTM are shown in (C–E). Here,
fixed concentrations (100 mM total sulfur) and incubation time (1 h) were employed. Peak H2S concentrations are
displayed in parts per million (ppm). The thiols used were reduced glutathione (GSH; 5 mM) and L-cysteine (Cys; 5 mM).
The dotted lines reflect typical H2S gas levels (3–4 ppm) obtained from ATTM (100 mM total sulfur) following 1 h
incubation at normal physiological pH and temperature. n = 3–6 per group.
https://doi.org/10.1371/journal.pmed.1002310.g001
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consumption in “hypoxic” tissues (Fig 2B; example trace, Fig 2C) had no effect under nor-
moxic conditions (Fig 2A).
Combined treatment with the non-sulfide-containing copper chelators neocuproine (Cu1+)
and cuprizone (Cu2+) had no effect in either model (S4A and S4B Fig; p = 0.30 and 0.48,
respectively).
To assess oxygen consumption in vivo, we placed awake, tethered, unrestrained rats into
metabolic cages. ATTM, given either as increasing IV bolus doses (Fig 2D) or as a continuous
infusion (Fig 2E), inhibited the whole body oxygen consumption of freely moving animals by
25% (p< 0.05). In rats that had received a continuous infusion for 24 h, we found that, com-
pared to vehicle-treated controls, core temperature decreased (Fig 2F; p< 0.05) and heart rate
(measured by echocardiography) fell by one-third (Fig 2G; p< 0.05).
Pharmacokinetics and pharmacodynamics
To better understand the pharmacological basis of this metabolic modulation, we performed
additional pharmacokinetic/pharmacodynamic (PK/PD) studies in anesthetized, mechanically
ventilated, and, importantly, normothermic rats. In a dose escalation study, bolus injection of
Fig 2. Inhibition of oxygen consumption by sulfide-containing drugs. (A) Ex vivo concentration response curves for ammonium tetrathiomolybdate
(ATTM) and NaHS in relative normoxia. Experiments were performed at 150–250 μM O2. In (B), tissues respired to hypoxia. Vehicle, ATTM (0.5 mM,
corresponding to 2 mM total sulfur), or NaHS (0.5 mM) was added at 200 μM O2. Note that oxygen consumption in vehicle-treated tissues also
decreases at lower [O2] (supply dependence) when tissues respire towards hypoxia. (C) shows a representative trace of tissues respiring to hypoxia,
with the timing of the following events indicated: a, sensitivity test; b, addition of tissue to the chamber; c, oxygenation; d, baseline measurements; e,
addition of ATTM or vehicle (control). (D) and (E) show the effects of ATTM in vivo following increasing, hourly IV bolus doses or a continuous infusion
(10 mg/kg/h), respectively. (F) shows core temperature and (G) shows echocardiography-derived heart rate at the end (24 h) of continuous infusion.
Panels A, B, D, and E show percentage inhibition compared to baseline values, before the addition of drugs. *p < 0.05 versus control using a two-way
repeated measures ANOVA (plus Bonferroni’s test in D and E) or unpaired t-test (in F and G). n = 3–12 for ex vivo experiments, and n = 4 per group for in
vivo studies.
https://doi.org/10.1371/journal.pmed.1002310.g002
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both ATTM and NaHS caused transient (<1 min) hypotension, although far higher (100-fold)
doses of ATTM were required to produce an equivalent peak fall in blood pressure, thus dem-
onstrating a superior safety profile (Fig 3A). In animals that received NaHS, significant quanti-
ties of H2S gas were measured in exhaled breath (Fig 3B). By contrast, and despite the fact that
ATTM caused similar hemodynamic effects at the highest dose, no H2S gas was detectable in
the exhaled breath of animals receiving ATTM, at any dose level. In animals administered
ATTM, a dose-dependent metabolic acidemia was observed, while the arterial partial pressure
of carbon dioxide (PCO2) remained unchanged (Fig 3C). A concurrent increase in blood lac-
tate levels and decrease in glucose (Fig 3D) reflect a greater reliance on non-mitochondrial res-
piration. Due to the distinct spectral characteristics of ATTM (Fig 3E), plasma levels could be
measured using a basic absorbance assay. Plasma concentrations (2 min post-injection) were
directly proportional to both the dose administered (Fig 3F) and subsequent (25 min later)
changes in arterial pH (Fig 3G), with the latter confirming a strong (r2 = 0.86) and straightfor-
ward PK/PD relationship.
Using the same model, we compared the alternative, bis-choline salt of tetrathiomolybdate,
known commercially as ATN-224 (Decuprate and WTX101), and found significantly less sul-
fide release in vitro (S5A Fig; p< 0.05). In vivo, the order of effect on arterial pH and lactate
(used here as biomarkers of inhibition of oxidative metabolism) was ATTM > ATN-
224> NaHS (S5B and S5C Fig). All three drugs caused comparable degrees of transient
Fig 3. Pharmacokinetic/pharmacodynamic studies. Maximal changes in mean arterial blood pressure (A) and detection of (peak) exhaled
H2S gas (in parts per million [ppm]) (B) following increasing IV bolus doses of ammonium tetrathiomolybdate (ATTM) or NaHS. No exhaled H2S
was detectable following ATTM administration. Acid/base interactions following ATTM treatment are shown in (C); the top left y-axis denotes
(arterial) partial pressure of carbon dioxide (PCO2); bottom left and right y-axes are (arterial) base excess and pH, respectively. Alterations in
(arterial) glucose and lactate following ATTM treatment are shown in (D). (E) shows the absorbance (ultra violet—visible) spectrum of ATTM with
(inset) a row of microplate wells used to construct a standard curve. (F) and (G) respectively show changes in ATTM plasma levels (measured
using the absorbance peak at 468 nm at 2 min after ATTM administration) against the quantity of drug administered and subsequent (25 min later)
changes in arterial pH. n = 3–4/group.
https://doi.org/10.1371/journal.pmed.1002310.g003
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hypotension at the highest dose level (S5D Fig), while circulatory (cardiac output) and respira-
tory (arterial PCO2) function remained unchanged (S5E and S5F Fig; p = 0.87 and 0.40, respec-
tively). As ATN-224 has the same (molybdenum-based) spectral signature as ATTM, we
compared their PK/PD relationships (S5G Fig). ATTM showed a greater fall in arterial pH rel-
ative to plasma concentration (slope in S5G Fig), thus reflecting greater potency.
Sulfhemoglobin formation and safety monitoring
In the PK/PD study outlined above, we observed a fall in percent oxyhemoglobin, despite no
change in the arterial partial pressure of oxygen (PaO2; Fig 4A). We postulated that this obser-
vation, a potentially deleterious side effect, could be due to either an acidosis-induced right-
ward shift of the hemoglobin dissociation curve or the formation of sulfhemoglobin. Given the
importance of safety monitoring in drug development, we designed an experiment to address
these hypotheses.
An infusion study in anesthetized rats (over 5 h) compared the effects of noncellular acido-
sis induced by IV hydrochloric acid administration and that induced by high-dose ATTM. We
further examined the reversibility of ATTM pharmacology using 70% inspired oxygen
(between 3 and 5 h). ATTM infused over 5 h reduced oxyhemoglobin levels (Fig 4B) to a simi-
lar magnitude as observed in the PK/PD study (Fig 4A). Continuous infusion of HCl also
caused an equivalent fall in arterial pH and oxyhemoglobin (Fig 4C and 4D), consistent with
an acidosis-induced rightward shift of the hemoglobin dissociation curve. As expected, an
increase in inspired oxygen concentration significantly elevated PaO2 (Fig 4E; p< 0.01).
While this fully reversed the ATTM-induced fall in oxyhemoglobin (Fig 4D), arterial pH
remained unchanged (Fig 4C; p = 1.0 for animals treated with ATTM versus ATTM + O2),
and respiratory function remained stable (Fig 4F; p = 0.25). Cardiac output decreased with
ATTM treatment (Fig 4G; p< 0.01), mainly due to a fall in heart rate. Despite this modest yet
significant fall in global oxygen delivery, interstitial skeletal muscle tissue oxygen tension
(tPO2), a marker of the local cellular oxygen supply/demand balance, was elevated (Fig 4H;
p< 0.05). This is indicative of adequate provision of oxygen, yet decreased utilization by
mitochondria.
Sulfhemoglobin levels were measured using an absorbance assay, taking advantage of the
differing spectral signatures of oxy- and sulfhemoglobin (Fig 4I). Sulfhemoglobin levels were
significantly (p< 0.05) elevated after 3 h of ATTM infusion, but fully reversible with increased
inspired oxygen (Fig 4J). Far higher drug concentrations were required for pathological sulfhe-
moglobin formation ex vivo (Fig 4K) than those achieved in the in vivo studies.
Ischemia/reperfusion models
The putative efficacy of ATTM was tested both in vitro and in three distinct, clinically relevant
in vivo models of I/R injury. In the first two models (organ-specific: heart and brain), ATTM
given at reperfusion significantly decreased infarct size (Fig 5A and 5D; p< 0.01 and p< 0.05,
respectively), myocardial-derived B-type natriuretic peptide (Fig 5B; p< 0.05), and brain-
derived S100 calcium binding protein β (Fig 5E; p< 0.05). Representative slices for each
model are shown in Fig 5C and 5F. For the heart model, the area at risk as a proportion of the
left ventricular area studied was similar across all groups (S6 Fig; p = 0.48), demonstrating that
the insult applied was of comparable severity.
In our in vitro model, ATTM given at reoxygenation significantly (p< 0.05) improved cell
viability (Fig 5G) in a concentration-dependent manner (S7A Fig). This was accompanied by a
substantial reduction in mitochondrial superoxide production (tested at the highest ATTM
concentration, 5.5 mM; Fig 5H). A representative flow cytometry plot (Fig 5G, right panel)
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and histogram for viability and superoxide production (Fig 5H, right panel) are shown. Incu-
bating cells with ATTM (without I/R) had no effect (p = 0.4) on viability (S7B Fig).
In our final (global) I/R model, ATTM significantly improved survival time (Fig 6A), such
that, at experiment end, twice as many ATTM-treated animals (10/16) were alive compared to
the group receiving vehicle (5/16; p< 0.05). Following reperfusion, the core temperature and
heart rate of vehicle-treated animals increased. ATTM commenced at the time of reperfusion
ablated these responses (Fig 6B and 6C; p< 0.001 for both) while maintaining global hemody-
namics, as evidenced by comparable cardiac output and blood pressure measurements (Fig 6D
and 6E; p = 0.05 and 0.42, respectively).
Fig 4. Safety studies. Effects of ammonium tetrathiomolybdate (ATTM) via either IV bolus dosing (A) or continuous infusion (B) on the arterial
partial pressure of oxygen (PaO2) and percentage of oxygenated hemoglobin (oxy Hb). For the continuous infusion study, changes in acid/base
balance, hemodynamics, and muscle tissue oxygen tension (tPO2) at experiment end (5 h) are shown in (C–H); dotted lines denote the average
baseline value. Where applicable, supplemental oxygen was commenced from 3 h. (I) shows the absorbance spectrum of oxy- and sulfhemoglobin,
used for calculation of sulfhemoglobin levels in vivo (in J; infusion study). Note that there was no absorbance overlap between either hemoglobin
form and ATTM (1 mM) at λ577/620. Formation of sulfhemoglobin ex vivo using either ATTM or NaHS to spike naïve rat blood is shown in (K). Here,
the dotted line represents the maximum sulfhemoglobin level. *p < 0.05 versus baseline (i.e., before the addition of ATTM) in panels A, B, and J
using a two-way ANOVA followed by Bonferroni’s testing; *p < 0.05 versus control (and ATTM versus ATTM + O2) in panels C–H using a one-way
ANOVA followed by Dunn’s multiple comparison test. n = 5–10 (in vivo), and n = 3 per group (ex vivo) in (K).
https://doi.org/10.1371/journal.pmed.1002310.g004
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Fig 5. Organ-specific ischemia/reperfusion and cellular anoxia/reoxygenation. Ammonium tetrathiomolybdate (ATTM) confers cardioprotection
(A–C, n = 6), neuroprotection (D–F, n = 6), and cytoprotection (G and H, ATTM 5.5 mM, n = 3). In (C), Evans blue dye shows the myocardial area not at
risk. In (C) and (F), viable tissue appears pink/red, with non-viable tissue depicted as white/beige. In (G) a representative flow cytometry plot denotes
positive (+ve) and negative (−ve) labeling for propidium iodide (PI) and Annexin V, expressed as median fluorescence intensity (MFI). Here, ATTM and
controls are depicted in dark red and black, respectively. Live cells (negative for both labels) are shown in the bottom left quadrant and as a percentage
of the total in the figure (G, left panel). The dotted line (G, left panel) shows viability in untreated cells (no ischemia/reperfusion or drugs). A
representative fluorescence histogram of MitoSOX (mitochondrial superoxide production) is shown in (H), right panel. AAR, area at risk; BNP, B-type
natriuretic peptide; IS, infarct size; S100β, S100 calcium binding protein β. *p < 0.05 using an unpaired t-test.
https://doi.org/10.1371/journal.pmed.1002310.g005
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Blood taken at 2 h post-reperfusion (before significant mortality) showed significantly
(p< 0.05) higher levels of GSH, a marker of antioxidant reserve capacity, in ATTM-treated
animals (Fig 6F), and a significant (p< 0.05) improvement in the ratio of GSH to GSSG, a
marker of oxidative stress (Fig 6G). This was accompanied by decreases in oxidative damage
(protein carbonyls; Fig 6H) and systemic inflammation (IL-6; Fig 6I); although the point esti-
mates for these biomarkers were different across treatment groups, the differences were not
statistically significant (p = 0.14 and 0.11, respectively) due to high variability in the control
arm.
Discussion
The last decade has seen considerable interest in sulfide as a putative adjunctive therapy during
resuscitation from various acute and critical illness states. Initial studies involved administra-
tion of H2S gas and simple, inorganic sulfide salts (Na2S and NaHS) that, when dissolved,
undergo instantaneous “generation” (rather than release) of sulfide [25]. Use of the latter has
implications for both safety and efficacy, and most likely precluded the clinical development of
treatments with these salts. More sophisticated drug design was clearly needed, and, as such, a
diverse range of slow-release sulfide “donors” have been synthesized. These range from phos-
phinodithioate analogues (e.g., GYY4137), dithiolethiones, and sulfide-hybrid drugs (e.g., S-
diclofenac) to persulfide-, gem-dithiol-, and N-mercapto-based donors [26–33].
Fig 6. Global ischemia/reperfusion study. Post-reperfusion survival times are shown in (A) for animals treated with ammonium
tetrathiomolybdate (ATTM) versus vehicle (control). *p < 0.05, log-rank test, n = 16 per group. Sequential changes in core temperature, heart rate,
cardiac output, and blood pressure are shown (B–E). *p < 0.05 using a two-way repeated measures ANOVA plus Bonferroni test. Note that this test
was only performed up to 2 h post-reperfusion due to early mortality. Measurements of (F) blood levels of reduced glutathione (GSH; antioxidant
reserve capacity), (G) the ratio of GSH to oxidized glutathione (GSSG) (lower values indicate greater oxidative stress), (H) protein carbonyls
(oxidative damage), and (I) interleukin-6 (IL-6; systemic inflammation) were performed at 2 h post-reperfusion, before the onset of significant
mortality. *p < 0.05, unpaired t-test.
https://doi.org/10.1371/journal.pmed.1002310.g006
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Our recognition that ATTM releases sulfide when dissolved in aqueous solution [19] has
been historically [34] and more recently [35] hypothesized. In addition, this feature has been
informally documented as a side effect (sulfur “burps”) following oral administration of the
bis-choline salt, ATN-224, which could be prevented by co-administration of an inhibitor of
gastric acid production [36]. Most recently, sulfide release was demonstrated in vitro; Xu et al.
reported that ATTM acts as a water-soluble, slow-release sulfide donor that is pH-sensitive
[37].
ATTM is not formally known as either a sulfide generator or a sulfide donor in the medical
literature. Although it shares characteristics of both, using recently updated nomenclature
[25], it is neither. Similarities between ATTM and the sulfide generators relate to their inor-
ganic structure and sensitivity to pH in aqueous solution. However, whereas the simple salts
release all sulfide when dissolved, ATTM releases sulfide in a linear fashion over time at physi-
ological pH and temperature, with increased sulfide release favored in warmer, more acidic
conditions. Sulfide release from all putative donors relies on some form of activation, with
mechanisms including hydrolysis, light, pH, and thiol activation. Surprisingly, combinations
of these factors that affect sulfide release are rarely addressed [26,37]. That ATTM releases sul-
fide spontaneously in aqueous solution in a pH-sensitive manner is indicative of hydrolysis;
however, we further found that ATTM can be thiol-activated in vitro. To our knowledge, no
sulfide donors activated by hydrolysis have shown additional sensitivity to biologically relevant
thiols. This has clear consequences for sulfide release in vivo, where thiols (particularly albu-
min in plasma and GSH intracellularly) may be present at levels capable of catalyzing this reac-
tion. In summary, our data demonstrate (1) that there are distinct differences in the nature of
sulfide release from NaHS and ATTM and (2) that the release of sulfide from ATTM differs
from that of other previously described sulfide-releasing drugs, being activated by a range of
chemical and biologically relevant factors. Taken together with the chemical characteristics of
ATTM, our findings position this molecule within a new class of sulfide-releasing drugs.
Our particular interest in sulfide relates to its ability to modulate metabolism and the impli-
cations this could have for the treatment of I/R injury. While the therapeutic potential of
hydrogen sulfide is well established, it is also toxic at higher concentrations [38], and this
restricts its use in patients. It modulates metabolism by potent inhibition of mitochondrial
cytochrome C oxidase (complex IV), thereby inhibiting oxidative phosphorylation and aerobic
generation of adenosine triphosphate (ATP) [39]. We compared the biological activity of
NaHS and ATTM ex vivo; while both could inhibit oxygen consumption, unsurprisingly
NaHS exhibited greater potency by its rapid generation of sulfide. A recent study using a hyp-
oxic cell model demonstrated that ATTM could inhibit complex IV, though this was assumed
to be mediated via a copper-dependent pathway involving hypoxia-inducible factor 1-alpha
[40]. We, too, found that oxygen consumption ex vivo was dependent on the local oxygen con-
centration. However, given the timeframe of action (seconds to minutes) in our experiments,
plus the lack of inhibitory activity of other non-sulfide-containing copper chelators, we con-
tend that the dependence of drug activity on local oxygen concentration relates to reduced oxi-
dation of sulfide under hypoxic conditions rather than an inducible or copper-dependent
biological mechanism.
In vivo, we found that the side effects of NaHS were dose-limiting, with a maximum toler-
ated (IV bolus) dose of 1 mg/kg. By contrast, far higher doses of ATTM (up to 100 mg/kg)
could be tolerated, despite exposure to a greater concentration of a sulfide-containing drug
with a substantially longer half-life. Using intermediate doses in awake rats allowed us to safely
reduce the whole body metabolic rate by 25%. Strikingly, in this model we observed that heart
rate fell by one-third, a pharmacological response that would considerably decrease myocar-
dial oxygen demand, yet without obvious injury or detriment to the animal.
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To better understand the impact of ATTM on global metabolism in vivo, we undertook
detailed PK/PD studies. A normothermic model ensured that responses were of a primary
pharmacological nature, and not confounded by secondary responses such as hypothermia.
Increasing IV bolus doses of ATTM caused a dose-dependent metabolic acidemia that
directly correlated with plasma concentrations. This, as well as the reduction in oxygen con-
sumption, supports our proposed intracellular mechanism of action at the level of the mito-
chondrion; when the lungs and/or circulation cannot deliver, or the mitochondria cannot
utilize, sufficient quantities of oxygen to sustain oxidative metabolism, cells increase both
ATP hydrolysis and glycolysis, both of which generate an excess of protons, and thus acide-
mia. The concurrent fall in blood glucose and rise in lactate also support this shift in metabo-
lism towards glycolysis following inhibition of oxidative phosphorylation. The lack of
significant change in arterial partial pressure of carbon dioxide and global oxygen delivery,
and the rise in skeletal muscle tissue oxygen tension, indicates ongoing cardiorespiratory
function that can still supply sufficient oxygen and substrate to adequately meet (albeit
reduced) metabolic demand [41].
We formally demonstrated that the bis-choline salt of tetrathiomolybdate, ATN-224,
releases sulfide in vitro, though to a lesser extent than ATTM. This feature explains its compar-
ative impotency in vivo with regards to acidemia and other secondary markers of mitochon-
drial inhibition. For ATN-224, this is a desirable feature; it is being developed as an oral agent
for use in Wilson disease and cancer [18,42]. Its copper-binding properties in the gastrointesti-
nal tract (copper is required for angiogenesis) require the molecule to remain intact for chela-
tion [43]. These data demonstrate that sulfide-releasing thiometallate drugs extend beyond
ATTM, that they vary in terms of their magnitude of sulfide release, and that their in vivo
potency can be predicted by a simple in vitro test.
ATTM has a good safety record in humans, having been used orally over long periods as a
copper chelating therapy (albeit off-label) for Wilson disease [15]. There are known side effects
related to copper depletion, most notably hematological events such as pancytopenia and ele-
vations in liver enzymes. However, these side effects have been documented only after chronic
administration, and they respond well to either dose reduction or drug holiday [18]. ATTM
has been assessed intravenously in a small series of patients with Wilson disease with no
reported safety concerns [17]. Although not addressed in the current study, we do not antici-
pate copper-related safety concerns with a single IV dose of ATTM given at reperfusion, as it
takes several weeks of therapy to deplete systemic copper levels [18].
As noted above, the nature of sulfide release from any putative medicine has implications
for safety and efficacy. Given that hydrogen sulfide has historically been regarded as an envi-
ronmental poison, with numerous reports of near-fatal intoxication [38,44,45], we considered
safety monitoring to be of particular importance in our study. As our preclinical studies indi-
cated utility for ATTM as an IV therapy against reperfusion injury, we were keen to address
hypotension and sulfhemoglobin formation in further detail, as these may represent limiting
complications. Sulfide-induced vasodilation is well recognized, with putative mechanisms
including covalent modification (sulfhydration) of the KATP channel, an inability to maintain
vascular tone due to ATP depletion, intracellular acidification, modulation of calcium signal-
ing, and release of lipid mediators [7]. NaHS, ATTM, and ATN-224 all caused transient hypo-
tension when given by bolus IV injection, though (compared to NaHS) far higher doses
(100-fold) of the thiometallates were required to elicit an equivalent blood pressure effect in
our healthy animals. While NaHS produced detectable levels of exhaled H2S gas (indicative of
free circulating sulfide), this outcome was not observed with ATTM or ATN-224 at any dose
level. This suggests that thiometallates release the majority of their sulfide within an extravas-
cular compartment. This is likely to occur intracellularly, where the microenvironment is
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more acidic and higher levels of thiols are present. The intense absorbance characteristics of
the molecule, while convenient for plasma determination, precluded affirmation of this postu-
late using flow cytometry with fluorescent probes. Notwithstanding this lack of confirmation,
the putative extracirculatory sulfide release generated far greater cellular metabolic potency in
vivo, i.e., increased acidemia for the same level of hypotension, thus demonstrating that, in our
animal model, targeted cellular delivery permits a superior safety window for ATTM over
rapid sulfide donors or generators.
The consistent fall in oxyhemoglobin saturation with ATTM, despite maintenance of arte-
rial oxygen partial pressure, suggested possible formation of sulfhemoglobin. While we could
generate significant sulfhemoglobin ex vivo, far higher concentrations of free sulfide (low mil-
limolar range) were required than we could encounter in vivo (micromolar range). Moreover,
high-dose administration of ATTM did generate a 1% sulfhemoglobin level in vivo, but this
does not account for the 15% fall in oxyhemoglobin saturation. A pH-induced right shift of the
hemoglobin dissociation curve is more likely, as reversal was seen following administration of
high oxygen concentrations.
Since elimination of sulfide is predominantly believed to be due to oxidation (largely occur-
ring in the mitochondria), we speculated that administration of oxygen could ameliorate all of
the pharmacological effects of ATTM and, in essence, offer an easily applied antidote. How-
ever, while the fall in oxyhemoglobin saturation and the low level sulfhemoglobin could be
reversed, arterial pH remained unchanged. This is in keeping with the proposed nature of sul-
fide binding at complex IV; although widely considered to be a reversible process, with sulfide
competing with oxygen in a similar manner to nitric oxide and carbon monoxide, detailed bio-
chemical experiments (albeit using purified proteins) revealed that inhibition is noncompeti-
tive with respect to cytochrome C and oxygen [6,46]. While this could explain the inability to
reverse the acidosis by high inspired oxygen concentrations, mice exposed to H2S gas made a
rapid, complete recovery upon cessation of administration [5]. It is unclear at present whether
the temporal nature of this recovery is species-specific.
Efficacy studies are the mainstay for preclinical proof of concept. Sulfide generators and
donors have shown a good track record in preclinical I/R studies; numerous reports have dem-
onstrated cardioprotection, neuroprotection, and outcome benefit [9,47,48]. Mechanisms pos-
tulated include preservation of mitochondrial function, modulation of inflammation and
apoptosis, enhanced angiogenesis, and reduced oxidative stress [7,13]. While secondary tissue-
specific pathways could confer benefit within particular organs, these pathways most likely
originate from an initial trigger. Both ischemia and reperfusion phases generate ROS that can
subsequently damage lipids, proteins, and DNA, and the majority of ROS derive from mito-
chondria [1]. During ischemia, the vitality of cells in the area at risk will be either irretrievable
or salvageable (closer to the surrounding penumbra). On revascularization, salvageable cells
are subjected to far greater restoration of nutrient supply than their metabolic state requires,
with enhanced substrate provision driving oxidative phosphorylation and generating large
quantities of ROS. We have shown efficacy in three distinct, clinically relevant in vivo I/R
models that supports a universal mechanism of action: that delivering a therapy to modulate
mitochondrial function decreases ROS production. This would be expected, as observed, to
enhance antioxidant reserve capacity and reduce oxidative stress and damage. The mechanistic
measures in our global I/R model and our in vitro I/R study support these claims. Additional
benefit may derive from a direct sulfide ROS scavenging effect and/or indirect effects such as
increased intracellular acidity enabling more rapid reduction of GSSG back to GSH [49].
Lastly, ischemic cells are more likely to exhibit decreased pH levels. Since sulfide release from
ATTM is pH-dependent, more sulfide may be released within cells that are more acidic and
therefore have a greater need for treatment.
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We demonstrated a beneficial effect for ATTM as a novel adjunct therapy for myocardial
and cerebral I/R injury, but its use in other emergency settings where modulation of metabo-
lism can potentially confer benefit also merits exploration. We found survival benefit when
ATTM was given at reperfusion following severe hemorrhage, and a previous study also dem-
onstrated that rats could tolerate greater blood loss when given a basic sulfide salt [8]. Preclini-
cal efficacy is also reported with sulfide in traumatic brain injury models [50,51].
Limitations
It is noteworthy for future study that not all sulfide detection assays are suitable for pH-sensi-
tive sulfide-releasing molecules such as ATTM. Xu et al. used a modified methylene blue assay,
mindful of the fact that pH alters sulfide release from this molecule [37]. In addition, our initial
pharmacokinetic comparison studies between ATTM and NaHS showed that certain fluoro-
phores and/or additives can potentially interact with the molecule. As such, we documented
high plasma levels of sulfide (mid-micromolar range) following ATTM treatment that, as free
sulfide, would not be compatible with life. We consider the majority of sulfide to be still bound
to the molecule and not bioavailable within the circulation. Since we used cysteine as an
adjunct to bind excess derivatizing agent, covalently bound sulfide would be made available by
thiol-induced release during sample processing with our modified MBB assay. This, and the
fact that the MBB reaction may detect additional reactive sulfur species [21], means that the
MBB and headspace H2S gas methods employed here reflect total and free sulfide, respectively.
Also noteworthy of consideration is the ATTM manufacturer. We found good consistency
across batches from one source but would urge other researchers to establish and standardize
sulfide release assays, if used for this purpose. Unfortunately, coloration (and consequent
absorption of incident light) of the molecule precluded measurement of intracellular sulfide
levels by flow cytometry using fluorescence probes such as WSP-1 [52] and POMAL-N3 [53].
Its coloration could also interfere with other absorption techniques such as the oximetry com-
ponent of arterial blood gas analysis and, potentially, the measurement of oxyhemoglobin satu-
ration. Penultimately, although animals in our awake, tethered model appeared clinically
normal with a 24-h infusion of ATTM, we did not perform any comprehensive behavioral test-
ing nor long-term follow-up. This will be addressed in future (certified) toxicology, safety, and
tolerability studies. Lastly, we acknowledge that our work is exclusively of a preclinical nature.
To this end, rigorous human testing will be additionally required to establish the safety of
ATTM (by IV administration) and its therapeutic utility for reperfusion injury in a clinical
setting.
Conclusion and development plan
Although the sulfide generators have so far fallen short of becoming new medicines, there is
precedent for reduced metabolism conferring protection in I/R injury in humans. For exam-
ple, an outcome benefit has been demonstrated from therapeutic hypothermia in various situa-
tions, including out-of-hospital cardiac arrest [54] and during myocardial revascularization
[55]. However, as this procedure is cumbersome and target temperatures are often not
achieved for 4–6 h, it has not proven universally beneficial [56]. ATTM could offer a safe,
rapid, and easily applied alternative. Importantly, it has a good safety record in humans that
includes IV use in patients [17], thus providing much encouragement for translation of this
compound to the clinical arena as a novel adjunct treatment for reperfusion injury. Our pri-
mary target is acute myocardial infarction, where ATTM could be delivered intravenously or
directly into the coronary circulation at the time of angioplasty.
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Supporting information
S1 Arrive Guidelines. A checklist providing reference to all aspects of animal experimenta-
tion performed in this study.
(DOCX)
S1 Fig. In vitro H2S gas released from different batches of ATTM. Batches 1–5 were from
the same commercial supplier, though from different manufacturer “lots.” No H2S gas was
detectable from batch 6, purchased elsewhere. The dotted lines reflect typical H2S gas levels
obtained from ATTM (100 mM total sulfur) following 1 h incubation at normal physiological
pH and temperature (3–4 ppm). n = 3/group.
(TIF)
S2 Fig. In vitro sulfide release using a monobromobimane-based assay. Sulfide release from
ATTM and NaHS at varying pH is shown in (A) and (B), respectively. Samples were incubated
at 37˚C. ATTM, 0.55 mM, and NaHS, 2.2 mM, were used to give equimolar sulfur concentra-
tions, as indicated by the dashed lines. Note that in our modified version of this assay we
added L-cysteine to bind excess MBB. This induces thiol-dependent release of sulfide from
ATTM. As such, between pH 4.5 and 10, ATTM releases approximately 80% of its bound sul-
fur as sulfide under these conditions. n = 4/group.
(TIF)
S3 Fig. Plasma sulfide concentrations following IV dosing in vivo. Monobromobimane-
derived plasma sulfide concentrations in rats receiving a bolus IV injection (A) or continuous
infusions (B) of ATTM. Bolus IV injections of ATTM and NaHS with comparable total sulfur
are shown in (C) to illustrate their fast “distribution” decay curves. (D) shows comparative
pharmacokinetics for ATTM and NaHS following IV bolus dosing. The slow “elimination”
half-life of NaHS was not determined (n/d) as plasma concentrations rapidly normalized.
n = 3–4 per group.
(TIF)
S4 Fig. Effects of non-sulfide-containing copper chelators on oxygen consumption in rat
soleus muscle ex vivo. Experiments were performed in (A) normoxia (150–250 μM O2) or
(B) hypoxia. In (A), increasing concentrations of combined neocuproine and cuprizone treat-
ment were used. In (B), combined treatment at a single concentration (100 μM of each) was
added at 200 μM O2, and tissues allowed to respire to hypoxia. Two-way repeated measures
ANOVA plus Bonferroni’s test revealed no significant differences between control (respiratory
medium) and copper chelator treatment. n = 8 per group.
(TIF)
S5 Fig. Comparative pharmacological assessment of sulfide-releasing drugs. (A) shows sig-
nificant differences in H2S gas release in vitro from ATTM and ATN-224.
p< 0.05, unpaired
t-test, n = 3. Dashed lines represent standard release under these conditions (3–4 parts per mil-
lion [ppm] after 60 min incubation at pH 7.4 and 37˚C). In vivo changes in acid/base balance
and hemodynamics at experiment end are shown in (B–F), i.e., following the highest dose of
each drug. Here, dashed lines represent the average baseline values obtained. p< 0.05 com-
pared to ATTM, one-way ANOVA plus Dunn’s multiple comparison test. (G) shows the PK/
PD relationships for ATTM and ATN-224. The slope represents the potency of each drug.
Since an absorbance assay was used here to determine plasma drug levels, the comparative
effects of (non-colored) NaHS were not determined. n = 3–4 per group.
(TIF)
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S6 Fig. Area at risk as a proportion of total area (left ventricle) following myocardial ische-
mia/reperfusion injury. p = 0.48 using an unpaired t-test, n = 6/group.
(TIF)
S7 Fig. In vitro cell studies. Concentration-dependent improvement in viability following I/R
with ATTM treatment (A) and no change in viability in normoxic cells (B). In (B), cells were
plated and maintained in a normoxic environment for 24 h, then treated with ATTM (5.5
mM) prior to analysis. p< 0.05 compared to vehicle (shown in Fig 5), one-way ANOVA plus
Dunn’s multiple comparison test.
(TIF)
S1 Text. A more detailed description of the following methods: monobromobimane assay,
in vivo surgical instrumentation, ex vivo metabolic study, and echocardiography.
(DOCX)
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